- Details
-
Created: Friday, 15 April 2016 09:59
Patrick Frost, Professor at UCLA and the West Los Angeles Medical Center, investigates how targeting angiogenesis and the adaptive hypoxic response in multiple myeloma cells affects tumor progression. He hopes his studies will provide insight into the pathology and chemotherapy resistance of this incurable disease, which occurs with a significant frequency in the Veteran population. He has been using the H35 HypOxystation for almost 3 years now, and he does not miss bygone days in the lab: “We started out with just a Plexiglas box, with some valves in it, with a front cover just held on magnetically, placed inside an incubator. We would burn through a 50 L tank of nitrogen in 48 hours. I was never convinced that we had the correct level of oxygen in there”.
Read more: HypOxystation Gas Consumption Studies
- Details
-
Created: Sunday, 13 March 2016 09:59
HypOxystation user Brad Wouters at the Princess Margaret Cancer Center in Toronto was a collaborator in a recent publication on “A three-dimensional engineered tumour for spatial snapshot analysis of cell metabolism and phenotype in hypoxic gradients“ (Rodenhizer et al., Nature Materials 15, 227–234, 2016). Dr. Wouters told HypOxygen that “we describe a new device that enables us to create naturally occurring oxygen gradients, such as the ones found in tumors. We use the HypOxystation to establish a baseline, as a control, on unrolled TRACER membranes …We can set the external concentration to a fixed oxygen level and look at the resulting gradients and metabolites and so on, too… The external level is what we define. That could be 20% oxygen, but it could also be 1% or 2%, and in that case we can have the rolled-up TRACER inside the hypoxia chamber. We have tried out various oxygen levels in the hypoxia workstation and the oxygen gradients in the TRACER are very different, as are the metabolite gradients.“
Read more: HypOxystation and the TRACER Project